Bard Second FTC Information Request May Portend Tyco Divestiture
This article was originally published in The Gray Sheet
Executive Summary
Bard is confident that its $3.2 bil. acquisition by Tyco will go through by year-end despite the intensified antitrust scrutiny by the Federal Trade Commission.
You may also be interested in...
Bard/Tyco
Pending merger is approved by Bard shareholders Aug. 7. The deal remains a subject of Federal Trade Commission scrutiny (1"The Gray Sheet" July 30, 2001, p. 12)
Bard/Tyco
Pending merger is approved by Bard shareholders Aug. 7. The deal remains a subject of Federal Trade Commission scrutiny (1"The Gray Sheet" July 30, 2001, p. 12)
Tyco Urology Franchise Leaps Ahead With $3.2 Bil. Bard Acquisition
Tyco International will increase its total health care sales to about $7.6 bil. annually through acquisition of C.R. Bard for approximately $3.2 bil. in stock. Valued at nearly three times Bard's 2000 sales of $1.1 bil., the definitive agreement was announced May 30.